New York, USA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Global Plasma Protein Therapeutics Market to Touch ~USD 40 Billion Mark by 2030 | DelveInsight The plasma protein therapeutics market is experiencing notable growth, driven by the essential role these therapies play in treating various conditions such as hemophilia, multiple sclerosis, and immune thrombocytopenia. By supplying crucial clotting factors, regulating immune functions, and enhancing patient outcomes, plasma protein therapeutics are becoming increasingly important.
With continuous advancements and broadening applications, the market is projected to see substantial expansion between 2024 and 2030. DelveInsight’s Plasma Protein Therapeutics Market Insights report provides the current and forecast market analysis, individual leading plasma protein therapeutics companies’ market shares, challenges, plasma protein therapeutics market drivers, barriers, trends, and key market plasma protein therapeutics companies in the market. Key Takeaways from the Plasma Protein Therapeutics Market Report As per DelveInsight estimates, the North American region is anticipated to dominate the global plasma protein therapeutics market during the forecast period.
In the application segment of plasma protein therapeutics, the hemophilia category had a significant revenue share in the year 2023. Notable plasma protein therapeutics companies such as Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Grifols, S.A.
, CSL, Baye.